Gordon Strathdee

Summary

Affiliation: University of Glasgow
Country: UK

Publications

  1. ncbi request reprint Control of gene expression by CpG island methylation in normal cells
    G Strathdee
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Glasgow University, Switchback Road, Glasgow G61 1BD, UK
    Biochem Soc Trans 32:913-5. 2004
  2. ncbi request reprint HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, CR UK Beatson Laboratories, G61 1BD UK
    Carcinogenesis 28:299-309. 2007
  3. ncbi request reprint Aberrant DNA methylation in cancer: potential clinical interventions
    G Strathdee
    Department of Medical Oncology, Cancer Research UK Beatson Laboratories, Glasgow University, Glasgow, G61 1BD, UK
    Expert Rev Mol Med 4:1-17. 2002
  4. ncbi request reprint Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene
    G Strathdee
    Department of Medical Oncology, Cancer Research UK Beatson Laboratories, Glasgow University, Glasgow G61 1BD, Scotland, UK
    Carcinogenesis 25:693-701. 2004
  5. ncbi request reprint Epigenetic versus genetic alterations in the inactivation of E-cadherin
    Gordon Strathdee
    Cancer Research Campaign Department of Medical Oncology, CRC Beatson Laboratories, Glasgow University, Glasgow G61 1BD, UK
    Semin Cancer Biol 12:373-9. 2002
  6. pmc Epigenetic markers and response to chemotherapy in cancer
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Glasgow University, Glasgow G61 1BD, UK
    Dis Markers 23:43-9. 2007
  7. ncbi request reprint Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Glasgow University, Glasgow G61 1BD, UK
    Gynecol Oncol 97:898-903. 2005
  8. ncbi request reprint Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker
    Jens M Teodoridis
    Centre for Oncology and Applied Pharmacology, CRUK Beatson Laboratories, Glasgow University, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK
    Drug Resist Updat 7:267-78. 2004
  9. ncbi request reprint CpG island methylation of DNA damage response genes in advanced ovarian cancer
    Jens M Teodoridis
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, University of Glasgow, Glasgow, United Kingdom
    Cancer Res 65:8961-7. 2005
  10. pmc Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes
    G Strathdee
    Cancer Research Campaign Department of Medical Oncology, CRC Beatson Laboratories, Glasgow University, Glasgow G61 1BD, United Kingdom
    Am J Pathol 158:1121-7. 2001

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Control of gene expression by CpG island methylation in normal cells
    G Strathdee
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Glasgow University, Switchback Road, Glasgow G61 1BD, UK
    Biochem Soc Trans 32:913-5. 2004
    ..Study of these examples will be important in identifying the mechanisms that control targeting of DNA methylation and how these processes are disrupted during disease pathogenesis...
  2. ncbi request reprint HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, CR UK Beatson Laboratories, G61 1BD UK
    Carcinogenesis 28:299-309. 2007
    ....
  3. ncbi request reprint Aberrant DNA methylation in cancer: potential clinical interventions
    G Strathdee
    Department of Medical Oncology, Cancer Research UK Beatson Laboratories, Glasgow University, Glasgow, G61 1BD, UK
    Expert Rev Mol Med 4:1-17. 2002
    ..Studies of DNA methylation in cancer have thus opened up new opportunities for diagnosis, prognosis and ultimately treatment of human tumours...
  4. ncbi request reprint Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene
    G Strathdee
    Department of Medical Oncology, Cancer Research UK Beatson Laboratories, Glasgow University, Glasgow G61 1BD, Scotland, UK
    Carcinogenesis 25:693-701. 2004
    ....
  5. ncbi request reprint Epigenetic versus genetic alterations in the inactivation of E-cadherin
    Gordon Strathdee
    Cancer Research Campaign Department of Medical Oncology, CRC Beatson Laboratories, Glasgow University, Glasgow G61 1BD, UK
    Semin Cancer Biol 12:373-9. 2002
    ....
  6. pmc Epigenetic markers and response to chemotherapy in cancer
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Glasgow University, Glasgow G61 1BD, UK
    Dis Markers 23:43-9. 2007
    ....
  7. ncbi request reprint Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Glasgow University, Glasgow G61 1BD, UK
    Gynecol Oncol 97:898-903. 2005
    ..The objective of this study was to determine the extent of MCJ promoter methylation in epithelial ovarian cancer patients and address the possible role of MCJ methylation levels in response to chemotherapy in ovarian cancer patients...
  8. ncbi request reprint Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker
    Jens M Teodoridis
    Centre for Oncology and Applied Pharmacology, CRUK Beatson Laboratories, Glasgow University, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK
    Drug Resist Updat 7:267-78. 2004
    ....
  9. ncbi request reprint CpG island methylation of DNA damage response genes in advanced ovarian cancer
    Jens M Teodoridis
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, University of Glasgow, Glasgow, United Kingdom
    Cancer Res 65:8961-7. 2005
    ..04, n = 56). This supports the hypothesis that genetic factors affecting function of DNMT genes may underlie the propensity of tumors to acquire aberrant CpG island methylation...
  10. pmc Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes
    G Strathdee
    Cancer Research Campaign Department of Medical Oncology, CRC Beatson Laboratories, Glasgow University, Glasgow G61 1BD, United Kingdom
    Am J Pathol 158:1121-7. 2001
    ....
  11. ncbi request reprint Epigenetic cancer therapies: DNA methyltransferase inhibitors
    Gordon Strathdee
    Cancer Research UK, Dept Medical Oncology, Beatson Laboratories, Glasgow University, Glasgow, G61 1BD, Scotland, UK
    Expert Opin Investig Drugs 11:747-54. 2002
    ..Agents that can reverse DNA methylation include nucleoside and non-nucleoside inhibitors of DNA methyltransferase. Such agents are now undergoing preclinical evaluation and clinical trials in cancer patients...
  12. ncbi request reprint Epigenomics and epigenetic therapy of cancer
    Robert Brown
    Cancer Research UK Dept of Medical Oncology, Beatson Laboratories, Glasgow University, Glasgow, UK G61 1BD
    Trends Mol Med 8:S43-8. 2002
    ....
  13. ncbi request reprint Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
    Kim Appleton
    Centre for Oncology and Applied Pharmacology, Glasgow University, Cancer Research UK Beatson Laboratories, Glasgow, United Kingdom
    J Clin Oncol 25:4603-9. 2007
    ..We designed a clinical study to determine the feasibility of delivering a dose of decitabine, combined with carboplatin, that would be capable of producing equivalent biologic effects in patients with solid tumors...
  14. ncbi request reprint Bioscience 2004
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, Glasgow University, Cancer Research UK, Beatson Laboratories, UK
    Pharmacogenomics 5:775-8. 2004
  15. ncbi request reprint Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
    J A Plumb
    Cancer Research Campaign Department of Medical Oncology, University of Glasgow, Bearsden, United Kingdom
    Cancer Res 60:6039-44. 2000
    ..Because there is emerging data on the role of loss of MMR in clinical drug resistance, DAC could have a role in increasing the efficacy of chemotherapy for patients whose tumors lack MLH1 expression because of hMLH1 promoter methylation...
  16. ncbi request reprint BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia
    Swagata Roy
    Department of Life Sciences, City Campus, Glasgow Caledonian University, Glasgow, UK
    Br J Haematol 157:446-56. 2012
    ..MECOM gene expression in CML-CP progenitor cells would provide an in vivo selective advantage, contributing to CML pathogenesis...
  17. ncbi request reprint CpG-island methylation and epigenetic control of resistance to chemotherapy
    J M Teodoridis
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, University of Glasgow, Glasgow, UK
    Biochem Soc Trans 32:916-7. 2004
    ....
  18. ncbi request reprint A role for mismatch repair in control of DNA ploidy following DNA damage
    G Strathdee
    CRC Department of Medical Oncology, CRC Beatson Laboratories, Glasgow University, Glasgow G61 1BD, UK
    Oncogene 20:1923-7. 2001
    ..These results suggest that loss of MMR on its own is not enough to overcome G2 arrest following exposure to cisplatin but does play a role in preventing polyploidization, or aberrant DNA reduplication, in the absence of functional p53...
  19. ncbi request reprint Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines
    A F Hurlstone
    Beatson Institute for Cancer Research, CRC Beatson Laboratories, Bearsden, Glasgow, UK
    Oncogene 18:1881-90. 1999
    ..CAVEOLIN-1 is however highly expressed in breast myoepithelial cells and its expression is retained in tumours derived from breast myoepithelium. Together our data refute a role for CAVEOLIN-1 as a breast tumour suppressor gene in vivo...
  20. ncbi request reprint Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours
    Janet C Lindsey
    Northern Institute for Cancer Research, The Medical School, University of Newcastle, Newcastle upon Tyne, United Kingdom
    Int J Cancer 118:346-52. 2006
    ....
  21. ncbi request reprint No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia
    Stefan Meyer
    Department of Paediatric Haematology and Oncology, Central Manchester and Manchester Children s University Hospitals NHS Trust, Manchester, UK
    Br J Haematol 134:61-3. 2006
    ..This does not exclude very low levels of FANCF, FANCB or NBS1 methylation, but suggests other factors are responsible for chemo-sensitivity and chromosomal instability in sporadic childhood leukaemia...
  22. ncbi request reprint Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers
    Susan H Wei
    Department of Pathology and Anatomical Sciences, Ellis Fischel Cancer Center, University of Missouri, Columbia, Missouri 65203, USA
    Clin Cancer Res 8:2246-52. 2002
    ..The purpose of this study was to profile methylation alterations of CpG islands in ovarian tumors and to identify candidate markers for diagnosis and prognosis of the disease...
  23. ncbi request reprint Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, Cancer Research UK
    Clin Cancer Res 13:5048-55. 2007
    ..We aimed to study the role of DNA methylation as an inducer of HOX gene silencing in leukemia...